Portopulmonary hypertension: a report from the US-based REVEAL Registry.

BACKGROUND We evaluated survival and hospitalization rates in patients with group 1 portopulmonary hypertension (PoPH) in the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry). METHODS The REVEAL Registry is a multicenter, observational, US-based study evaluating demographics and management of patients with pulmonary arterial hypertension (PAH). Outcomes were examined using Kaplan-Meier time-to-event estimates and compared with patients with idiopathic PAH (IPAH) or familial PAH (FPAH). RESULTS One hundred seventy-four patients with PoPH were enrolled in the REVEAL Registry (IPAH/FPAH; n = 1,478) from March 2006 to December 2009. Mean age was 53 ± 10 years, 52% were female, 32% were newly diagnosed, and 6% were New York Heart Association/World Health Organization functional class IV. Outcome parameters were worse for PoPH vs IPAH/FPAH, respectively: 2-year survival from enrollment (67% vs 85%, P < .001), 5-year survival from time of diagnosis (40% vs 64%, P < .001), and 2-year freedom from all-cause hospitalization (49% vs 59%, P = .019). However, despite worse outcomes, hemodynamic parameters at diagnosis were better for PoPH vs IPAH/FPAH, respectively: mean pulmonary artery pressure (49 mm Hg vs 53 mm Hg, P < .001), mean right atrial pressure (9 mm Hg vs 10 mm Hg, P = .005), pulmonary vascular resistance (8 Wood units vs 12 Wood units, P < .001), and cardiac output (5 L/min vs 4 L/min, P < .001). Compared with patients with IPAH/FPAH, patients with PoPH were less likely to be on a PAH-specific therapy at enrollment (P < .001), suggesting potential delays in therapy for patients with PoPH. CONCLUSIONS Patients with PoPH had significantly poorer survival and all-cause hospitalization rates compared with patients with IPAH/FPAH, despite having better hemodynamics at diagnosis. Further studies should investigate such outcomes and differences in treatment patterns. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

[1]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[2]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[3]  G. Raskob,et al.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. , 2010, Chest.

[4]  R. Wiesner,et al.  Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  M. Humbert,et al.  Portopulmonary hypertension: survival and prognostic factors. , 2008, American journal of respiratory and critical care medicine.

[6]  G. Raskob,et al.  Design of the REVEAL registry for US patients with pulmonary arterial hypertension. , 2008, Mayo Clinic proceedings.

[7]  R. Wiesner,et al.  Portopulmonary hypertension: Results from a 10‐year screening algorithm , 2006, Hepatology.

[8]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[9]  S. Kimmel,et al.  Hemodynamics and survival of patients with portopulmonary hypertension , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  R. Carithers,et al.  Practice Guidelines : Evaluation of the Patient for Liver Transplantation , 2005 .

[11]  R. Rodríguez-Roisín,et al.  Pulmonary–Hepatic vascular Disorders (PHD) , 2004, European Respiratory Journal.

[12]  J. Benson,et al.  Hepatopulmonary syndrome and portopulmonary hypertension: A report of the multicenter liver transplant database , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  R. Wiesner,et al.  Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  W. Edwards,et al.  A spectrum of pulmonary vascular pathology in portopulmonary hypertension , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[15]  G. Klintmalm,et al.  Severe pulmonary hypertension in liver transplant candidates. , 1997, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  A. Hadengue,et al.  Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. , 1991, Gastroenterology.

[17]  B. Groves,et al.  26. Pulmonary Hypertension Associated with Hepatic Cirrhosis , 1990 .

[18]  N Keiding,et al.  Confirmatory analysis of survival data using left truncation of the life times of primary survivors. , 1987, Statistics in medicine.

[19]  G. Hutchins,et al.  Primary pulmonary hypertension and cirrhosis: are they related? , 2015, The American review of respiratory disease.